跳至主要内容
临床试验/NCT00123669
NCT00123669已完成2 期

The Primary Progesterone Therapy for Operable Breast Cancer : A Randomized Controlled Trial

Tata Memorial Hospital1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 1997年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
1,000
试验地点
1
主要终点
To test the effect of primary progesterone in operable breast cancer on overall and disease free survival at 5 years

研究概览

简要总结

The purpose of this study is to test the effect of primary progesterone on overall and disease free survival in women with operable breast cancer. The study addresses two issues related to breast cancer surgery:

  • Circulating progesterone at the time of surgery might counteract the detrimental effect of estrogen on survival of women with operable breast cancer.
  • Events at the time of surgery may have an impact on the natural history of breast cancer

详细描述

This protocol addresses the issue of pre-operative hormone manipulation in women with operable breast cancer. The study has been designed after careful review of literature to assess the effect of unopposed oestrogen at the time of surgery and collect evidence that events at the time of surgery may have impact on the long-term survival of breast cancer patients. The meta-analysis of 37 studies on timing of surgery during the menstrual cycle showed a 15% + 3 improvement in survival for women who had undergone surgery during the luteal phase of their menstrual cycle. Three of the 37 studies where progesterone levels were estimated at the time of surgery showed 52% + 26 improvement in survival when circulating progesterone were > 1.5 ng/ml. The study aims to produce luteal milieu by injecting Hydroxy- progesterone 500 mg IM at the time of surgery. The timing of administration of progesterone in the neo-adjuvant setting is decided after collating data from large data-bases and randomised trials of screening suggesting that events at the time of surgery may alter the behavior of micro-metastases.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Unilateral operable palpable breast cancer

排除标准

  • Previous history of excision biopsy of the primary tumour
  • History of other epithelial/mesenchymal malignant tumours except basal cell carcinoma/squamous cell carcinoma (BCC/SCC) of skin

研究组 & 干预措施

Treatment

Experimental

An intramuscular injection of 500mg depot hydroxy-progesterone 5-14 days prior to surgery.

干预措施: 500 mg of depot hydroxy-progesterone (Drug)

结局指标

主要结局

To test the effect of primary progesterone in operable breast cancer on overall and disease free survival at 5 years

时间窗: 5 years

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Dr Rajendra A. Badwe

Director

Tata Memorial Centre

研究点 (1)

Loading locations...

相似试验